WCLC 2025 - Posters & ePosters-P3.18.52 Phase 3 Trial ResQ201A of NAI Plus Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced or Metastatic NSCLC Resistant to ICI Therapy

P3.18.52 Phase 3 Trial ResQ201A of NAI Plus Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced or Metastatic NSCLC Resistant to ICI Therapy

Back to course

Asset Subtitle

Leylah Drusbosky

Meta Tag

Speaker Leylah Drusbosky

Topic Clinical Trials in Progress